Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
10.0
5.5
Journals
Pharmaceutics
Special Issues
Next-Generation Biomaterials for Oral Healthcare: Focus on Regenerative and Delivery...
share announcement

Next-Generation Biomaterials for Oral Healthcare: Focus on Regenerative and Delivery Functions

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 2091

Special Issue Editor

Dr. Giuseppina Nocca

E-Mail Website
Guest Editor
1. Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Sezione di Biochimica, Università Cattolica del Sacro Cuore, Roma, Italy
2. Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
Interests: cell–material interactions; drug delivery; biological characterization of nano- and micromaterials
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Next-generation biomaterials are revolutionizing oral healthcare by combining regenerative capabilities with advanced drug delivery functions. These innovative materials offer non-invasive, patient-friendly, and cost-effective approaches for the treatment of both local and systemic diseases affecting the oral cavity and beyond. Recent advances in pharmaceutical and material sciences have led to the development of multifunctional oral biomaterials capable of targeted drug delivery, controlled release, enhanced bioavailability, and improved therapeutic outcomes, while simultaneously promoting tissue regeneration and repair.

A key focus of this Special Issue is the exploration of biomaterials with mucoadhesive, bioactive, and biocompatible properties, which prolong drug retention, optimize absorption at mucosal surfaces, and support the regeneration of oral tissues. This collection will highlight cutting-edge innovations in mucoadhesive systems, nanotechnology-based platforms, bioactive scaffolds, and smart delivery systems tailored for oral applications. Contributions will include preclinical and clinical research, as well as in vitro and ex vivo studies, providing valuable insights into the interaction between advanced biomaterials, drug formulations, and the unique biological environment of the oral cavity.

This Special Issue aims to address current challenges in overcoming physiological barriers, enhancing drug solubility and stability, and designing regenerative solutions for oral tissues. By bringing together interdisciplinary perspectives, this Special Issue offers a comprehensive overview of next-generation biomaterials for oral healthcare, fostering innovation and collaboration in the development of advanced therapeutics to meet the evolving needs of modern dentistry and oral medicine.

Dr. Giuseppina Nocca
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • oral drug delivery

  • biomaterials
  • mucoadhesive systems
  • nanotechnology
  • regenerative dentistry
  • oral tissue engineering
  • bioactive scaffolds
  • controlled drug release
  • oral mucosal drug absorption
  • smart biomaterials
  • in vitro and ex vivo models
  • oral healthcare innovation

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 1034 KB  
Article
In Vitro Oral Cavity Permeability Assessment to Enable Simulation of Drug Absorption
by Pankaj Dwivedi, Priyata Kalra, Haiying Zhou, Khondoker Alam, Eleftheria Tsakalozou, Manar Al-Ghabeish, Megan Kelchen and Giovanni M. Pauletti
Pharmaceutics 2025, 17(7), 924; https://doi.org/10.3390/pharmaceutics17070924 - 17 Jul 2025
Viewed by 675
Abstract
Background/Objectives: The oral cavity represents a convenient route of administration for drugs that exhibit significant hepatic first-pass extraction. In this study, the mucosal permeation properties of selected active pharmaceutical ingredients (APIs) incorporated into oral cavity drug products that are approved by the U.S. [...] Read more.
Background/Objectives: The oral cavity represents a convenient route of administration for drugs that exhibit significant hepatic first-pass extraction. In this study, the mucosal permeation properties of selected active pharmaceutical ingredients (APIs) incorporated into oral cavity drug products that are approved by the U.S. Food and Drug Administration were quantified using the human-derived sublingual HO-1-u-1 and buccal EpiOral™ in vitro tissue models. Methods: Epithelial barrier properties were monitored using propranolol and Lucifer Yellow as prototypic transcellular and paracellular markers. APIs were dissolved in artificial saliva, pH 6.7, and transepithelial flux from the apical to the basolateral compartment was quantified using HPLC. Results: Apparent permeability coefficients (Papp) calculated for these APIs in the sublingual HO-1-u-1 tissue model varied from Papp = 2.72 ± 0.06 × 10−5 cm/s for asenapine to Papp = 6.21 ± 2.60 × 10−5 cm/s for naloxone. In contrast, the buccal EpiOral™ tissue model demonstrated greater discrimination power in terms of permeation properties for the same APIs, with values ranging from Papp = 3.31 ± 0.83 × 10−7 cm/s for acyclovir to Papp = 2.56 ± 0.68 × 10−5 cm/s for sufentanil. The tissue-associated dose fraction recovered at the end of the transport experiment was significantly increased in the buccal EpiOral™ tissue model, reaching up to 8.5% for sufentanil. Conclusions: Experimental permeation data collected for selected APIs in FDA-approved oral cavity products will serve as a training set to aid the development of predictive computational models for improving algorithms that describe drug absorption from the oral cavity. Following a robust in vitro–in vivo correlation analysis, it is expected that such innovative in silico modeling strategies will the accelerate development of generic oral cavity products by facilitating the utility of model-integrated evidence to support decision making in generic drug development and regulatory approval. Full article
(This article belongs to the Special Issue Next-Generation Biomaterials for Oral Healthcare: Focus on Regenerative and Delivery Functions)
►▼ Show Figures

Graphical abstract

25 pages, 6641 KB  
Article
Development of an Innovative Dual Construct for Targeted Drug Delivery in the Oral Cavity
by Elena Mazzinelli, Ilaria Favuzzi, Marianna Messina, Giorgia Fratocchi, Federica Vincenzoni, Eleonora Santo Stefano, Francesco Cecconi, Carlo Lajolo, Alessia Basco, Raffaella Castagnola, Massimo Cordaro, Francesco Scilla, Valerio Papa, Alessandro Arcovito, Ilaria Cacciotti and Giuseppina Nocca
Pharmaceutics 2025, 17(2), 272; https://doi.org/10.3390/pharmaceutics17020272 - 18 Feb 2025
Cited by 1 | Viewed by 1061
Abstract
Background: Oral lichen planus (OLP) is a chronic autoimmune disease of the oral mucosa, classified among potentially malignant oral disorders (OPMDs). It is characterized by keratinocyte apoptosis and persistent inflammation. Standard treatments involve topical corticosteroids administered via mouthwashes, gels, or ointments, but these [...] Read more.
Background: Oral lichen planus (OLP) is a chronic autoimmune disease of the oral mucosa, classified among potentially malignant oral disorders (OPMDs). It is characterized by keratinocyte apoptosis and persistent inflammation. Standard treatments involve topical corticosteroids administered via mouthwashes, gels, or ointments, but these require frequent application, have limited retention, and may cause side effects. To address these limitations, this study aimed to develop an innovative dexamethasone delivery system targeting the oral cavity, based on poly(lactic acid) (PLA) fibers coated with chitosan (CS) and poly(lactic-co-glycolic acid) (PLGA) nanoparticles. Methods: CS-coated PLA fibers were characterized for their mucoadhesive and cytocompatibility properties, while PLGA nanoparticles were analyzed for size, shape, encapsulation efficiency, cellular uptake, drug release efficiency, and cytocompatibility. Results: Both polymers demonstrated cytocompatibility, and chitosan-coated PLA fibers exhibited mucoadhesive properties. PLGA nanoparticles were effectively internalized by the cells and successfully released the drug into the cytoplasm. The combination of CS-coated PLA fibers and PLGA nanoparticles provided dual benefits: mucoadhesion and efficient cellular uptake, even under conditions simulating salivation. Conclusions: These findings highlight the potential of the proposed system to improve mucoadhesive drug delivery. Further optimization is needed to enhance patient compliance and therapeutic efficacy. Full article
(This article belongs to the Special Issue Next-Generation Biomaterials for Oral Healthcare: Focus on Regenerative and Delivery Functions)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop